Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 4:47 AM
Ignite Modification Date:
2025-12-25 @ 4:47 AM
NCT ID:
NCT02876718
Eligibility Criteria:
Inclusion Criteria:
* Female and male patients ≥ 20 years of age (legal age limit in Taiwan) with a confirmed diagnosis of AF (non-valvular).
* Treatment with VKA for at least 6 weeks.
* Decision to initiate treatment with Rivaroxaban has been made as per investigator's routine treatment practice.
* Written informed consent of the patient.
* Wilingness and capability to conduct two F2F interviews.
Exclusion Criteria:
* Contraindications to the use of Rivaroxaban as outlined in the local product information .
* Concomitant treatment with any other anticoagulants.
* Participation in another study (clinical intervention/observational) within the 3 months prior to enrollment.
* Patients participating in an investigational program with interventions outside of routine clinical practice.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
20 Years
Study:
NCT02876718
Study Brief:
Protocol Section:
NCT02876718